0000000000754918

AUTHOR

E. Tirri

showing 1 related works from this author

AB0467 EFFECTIVENESS OF GOLIMUMAB AFTER TNF-INHIBITOR FAILURE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, OR AXIAL SPONDYLOART…

2021

Background:Golimumab showed trial efficacy in subjects with active rheumatoid arthritis (RA) previously treated with TNF-inhibitors (TNFi); no trial data are available for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).Objectives:To assess the effectiveness of golimumab after TNFi failure in patients with RA, PsA, or axSpA in a real-world setting.Methods:GO-BEYOND-Italy is an ongoing, multicenter, prospective, observational study of RA, PsA, or axSpA patients starting golimumab after TNFi failure. Patients were enrolled between July 2017 and December 2019, and followed for 1 year, with evaluations at 3, 6, and 12 months. This interim analysis estimates the effectiveness after…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentImmunologymedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyInfliximabGolimumabTNF inhibitorEtanerceptPsoriatic arthritisRheumatologyRheumatoid arthritisInternal medicinemedicineAdalimumabImmunology and AllergyAxial spondyloarthritisbusinessmedicine.drugAnnals of the Rheumatic Diseases
researchProduct